Navigation Links
Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
Date:4/20/2009

t not exclusively those addressing future performance or timelines for regulatory approvals, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products, the results of enrollment in and timing of clinical trials, including the HeartMate II, the effects of FDA regulatory requirements and the effects of healthcare reimbursement and coverage policies. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading "Risk Factors" in Thoratec's most recent annual report on Form 10-K and as may be updated in subsequent SEC filings. These forward-looking statements speak only as the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
4. Thoratec Presentation at JP Morgan Conference to be Webcast
5. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
6. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
8. Thoratec Presentation at J.P. Morgan Conference to be Webcast
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... , New GeneConnection discovery microarrays provide more than 4,000 unique,human cDNA sequences ... a series of human cDNA microarrays on , ... which are based on the technology published by Schena et , ... monitoring RNA expression levels , of genes. ...
... with standardized clones , , Rebecca L. ... Wynne Vilma Nioko ,Leonardo DeLeon SanDEe Soares ... Spencer Stevens Chris Hansen Brian Schilling ,Phenogenex ... a single dual- expression vector. These clones eliminate the ...
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
Cached Biology Technology:Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 2Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 3Stratagenes Human cDNA Microarrays: Perform Gene Expression Profiling and,Discover New Genes 4Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 2Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 3Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 4Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 5Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression,Vector 6Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3
(Date:9/18/2014)... a small, icy moon of Uranus, is one of ... solar system. Despite its relatively small size, Miranda appears ... resulted in the formation of at least three remarkable ... , These coronae are visible in Miranda,s southern ... across. Arden corona, the largest, has ridges and troughs ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Station ever starts a "frequent flyers" program, fruit flies ... orbiting laboratory has hosted increasing numbers of fruit fly ... space station in April, and another is scheduled launch ... planned to launch in December. , Fruit flies are ... and in space. Model organisms can reveal the basis ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... with dogs and using the latest in imaging software and ... heart specialists have developed a fast and accurate means of ... the coronary arteries. Researchers say it took them less ... echocardiograms currently used to find early warning of vessels more ...
... approach, researchers at Children's Hospital Boston have demonstrated that ... a heart attack and protect the heart from scarring. ... a natural inhibitor of cell division with a naturally ... Together, these two agents enabled heart-muscle cells to multiply ...
... Researchers at the Salk Institute for Biological Studies in collaboration ... took a high resolution "action shot" of a protein switch ... nervous system. Their findings, published in the Dec. 8 issue ... design of small molecule inhibitors to control that switch, a ...
Cached Biology News:Fast test for low blood flow in dogs detects early heart trouble 2Fast test for low blood flow in dogs detects early heart trouble 3Fast test for low blood flow in dogs detects early heart trouble 4Rescuing injured hearts by enhancing regeneration 2Rescuing injured hearts by enhancing regeneration 3Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 2Detailed 3-D image catches a key regulator of neural stem cell differentiation in action 3
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... converts any scanner into a gel densitometer. ... features, the basic operation simply consists of ... etc.) into pixel density / intensity values ... Turn your scanner into a high ...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... effectively in tubes and 96 well plates. microCLEAN ... one and a half spin DNA cleanup reagent. ... concentrate any type of double stranded DNA, efficiently ... dNTPs (labelled or unlabelled). It is therefore ideally ...
Biology Products: